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improvement in nasal symptoms (congestion and hydrorrhea, and, 
to a lesser extent, hyposmia); 2 months later she had also achieved 
better asthma control (no further need for rescue bronchodilator 
use and no asthma symptoms, leading to the withdrawal of inhaled 
corticosteroids and long-acting ß2 agonists, and a signifi cant 
improvement of FEV1 up to 90% of predicted). After 16 weeks 
of treatment with omalizumab, the Asthma Control Test score had 
risen from 11 to 25 points, and the asthma-related quality of life 
questionnaire (AQLQ) revealed a score of 6.8. Before starting the 
anti-IgE therapy, she had a severely impaired quality of life, with 
an AQLQ of 3.68 (>1.5 points improvement).
In September 2009, a specifi c bronchial challenge with 
lysine-acetylsalicylate yielded a negative result, and in 
October 2009, an oral challenge with aspirin with a cumulative 
dose of 750 mg was also negative. In the follow-up visit in 
December 2009, a certain degree of hyposmia persisted, despite 
continuous therapy with intranasal corticosteroids, and the 
methacholine test was still positive (PC20, 1.84 mg/mL). The 
patient, however, had no asthma symptoms under treatment 
with montelukast and omalizumab only. She had also tolerated 
ibuprofen 600 mg perfectly on several occasions. 
Omalizumab could prove effective in the treatment of 
AERD, as demonstrated by the experience of our patient, who 
not only succeeded in controlling the disease and signifi cantly 
improving her quality of life but is also now capable of 
tolerating aspirin and other COX-1 inhibitors. Further 
studies are required in order to confi rm the effectiveness of 
omalizumab in patients with AERD.
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While cutaneous delayed-type hypersensitivity to topical 
corticosteroids is common, immediate reactions to systemic 
corticosteroids (SC) are rare, with little more than 100 cases 
reported [1-3]. Anaphylaxis and other types of immediate 
reaction to SCs (including urticaria, angioedema, and 
bronchospasm) have been described [4-6]. Hydrocortisone, 
prednisolone, and methylprednisolone are the agents most 
frequently implicated [1,7,8], although hypersensitivity to 
dexamethasone is exceedingly rare. Not only should the 
corticosteroid itself be considered potentially responsible, 
but its specifi c ester, and even the excipients (especially 
carboxymethylcellulose), should be also be taken into 
account [1,9]. 
We retrospectively studied all patients attending the 
drug allergy clinic at Coimbra University Hospitals in 
the last 10 years with an immediate reaction to SCs and 
positive skin test results. Clinical records were consulted 
to obtain information on concomitant medication, timing of 
administration, the reaction, and treatment. Skin prick tests 
(SPT) to parenteral dexamethasone, methylprednisolone, 
hydrocortisone, prednisolone, and latex had been performed 
using an undiluted formulation. 
If the SPT results were negative, intradermal tests 
(IDT) to the same SC were performed in 10-fold increasing 
concentrations (0.002 mg/dL, 0.02 mg/dL, 0.2 mg/dL). Ten 
atopic volunteers (controls) also underwent the same skin 
tests. Specifi c immunoglobulin (Ig) E to methylprednisolone 
(PhadiaTM, Uppsala, Sweden) was determined in the most 
recent reactions (patients 3 and 6).
All patients gave their informed consent to undergo an 
oral challenge test with defl azacort (cumulative dose, 60 mg). 
Dexamethasone was also tested in patients 3 and 5.
Six patients (4 women/2 men, mean [SD] age 48.2 [13.6] 
y) were evaluated. All had been administered the suspect SC 
intravenously. All SPTs to latex were negative. The results are 
summarized in the Table. 
All atopic controls had negative skin test results. 
Specific IgE to methylprednisolone was positive in 
patient 3 (1.6 kUA/L). The challenge test with defl azacort was 
negative in all patients; the challenge test with dexamethasone 
was positive in patient 5. 
Although the most frequent manifestations were 
cutaneous, life-threatening anaphylaxis with hypotension 
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Table. Population and Skin Test Results
Patient Signs and SC
 Time From                          Skin Tests
Symptoms Implicated Reaction to     
Associated
    Skin Tests, y D MP H P Condition
           
 1 Bronchospasm MP 6 SPT (–) SPT (–) SPT (–) SPT (–) Atopic
     IDT (–) IDT (+) IDT (–) IDT (ND) asthma
      (0.002 mg/dL)
 2 Bronchospasm P 13 SPT (–) SPT (–) SPT (–) SPT (–) AERD
     IDT (ND) IDT (–) IDT (ND) IDT (+)
        (0.002 mg/dL)
 3 1st episode: U, H 2 months SPT (–) SPT (+) SPT (+) SPT (+)
  AE, hypotension   IDT (–) IDT (ND)
 4 1st episode: U 
  2nd episode:    SPT (–) SPT (–)
  bronchospasm, 1st, MP 7 SPT (–) IDT (+) IDT (+) SPT (–) AERD
  anaphylactic 2nd, P  IDT (–) (0.002 mg/dL) (0.2 mg/dL) IDT (ND)
  shock
 5 Anaphylactic    SPT (–)
   MP 13 SPT (–) IDT (+) SPT (–) SPT (–)  Atopic
     IDT (–) (0.02 mg/dL) IDT (–) IDT (–) asthma
 6 Bronchospasm P 3 SPT (–) SPT (–) SPT (–)   SPT (–) Atopic
     IDT (–) IDT (+) IDT (–) IDT (–) asthma
      (0.2 mg/dL)  (0.02 mg/dL) 
Abbreviations: AE, angioedema; AERD, aspirin-exacerbated respiratory disease; D, dexamethasone; H, hydrocortisone; IDT, intradermal test; SC, systemic corticosteroid; MP, methylprednisolone; P, prednisolone; SPT, skin prick test; U, urticaria.
occurre in 2 patients. Latex allergy and concomitant drug 
hypersensitivity were ruled out in all participants. In contrast to 
the results of previous reports [1,7], hypersensitivity attributed 
to hydrocortisone was rare, and both methylprednisolone and 
prednisolone were the most commonly implicated SCs in 3 
out of 6 patients each. This may be related to the generalized 
use of these SCs in our hospital.
The literature associates intravenous administration with a 
higher frequency of hypersensitivity reaction [1]. Our results 
support this association, as the drugs were administered 
intravenously in all patients.
Consistent with the fi ndings of other studies, the positive 
skin test results we observed point to an IgE-mediated reaction 
[1,3,8].
In our population, 3 out of 6 patients were sensitized to 
2 or more corticosteroids, suggesting cross-reactivity. This 
has also been observed by some authors [2,8,10], but not by 
others [1].
Defl azacort was well tolerated in all cases, thus proving 
to be a viable alternative. Similar results have been reported 
elsewhere [8,10]. The results of skin tests to dexamethasone 
were negative, suggesting that it may be an appropriate 
parenteral option, although the result of challenge testing was 
positive in a patient with a negative skin test result. 
Asthma and renal transplant have been identifi ed as risk 
factors for hypersensitivity to SCs [7]. This is supported in our 
series, as 5 out of 6 patients were asthmatics.
In conclusion, although rare, immediate reactions to SCs 
can be life-threatening. Both IgE-mediated and non–IgE-
mediated mechanisms have to be considered, and skin tests 
can be a valuable ally in the workup. Cross-reactivity can 
occur between different corticosteroids. Finally, defl azacort 
seems to be a viable alternative in patients who experience 
hypersensitivity reaction to SCs.
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The anti-immunoglobulin (Ig) E monoclonal antibody 
omalizumab (Xolair) has been proposed as an innovative 
pharmacological tool in the treatment of poorly controlled 
moderate to severe allergic asthma, which is characterized by 
frequent exacerbations, functional instability, and the need for 
high-dose inhaled corticosteroids, systemic corticosteroids, 
or both [1-3]. 
Management of severe asthma can benefi t from both 
prospective and retrospective monitoring in order to control 
the disease and prevent exacerbations [4,5].
We developed a retrospective monitoring procedure 
based on daily recording of the symptom score and of peak 
expiratory fl ow (PEF), which we routinely apply for as long 
as 10 months (or more, when necessary) in new patients with 
poorly controlled severe asthma. The valuable information 
we collect enables us to confi rm our diagnosis and fi ne-tune 
therapy. The data recorded by patients at follow-up visits on 
monitoring cards are processed in real time by the graphic 
software Sigmaplot 1.0-11.0 (Systat, London, UK), which 
produces high-quality self-explanatory charts that can aid 
management-related rapid decision making through visual 
pattern recognition [5].
We describe our application of these monitoring techniques 
in patients with severe asthma treated with omalizumab (at 
the recommended individually tailored dose). The procedure 
has enabled us to assess the clinical and functional effects 
of omalizumab on asthma before and after treatment in a 
measurable and detailed manner (as in 4 of the 35 cases we 
are currently managing).
As an example of this concept, the Figure depicts the results 
for a 52-year-old male farmer sensitized to Parietaria judaica 
(a perennial allergen in Southern Italy), grass pollen, cypress 
pollen, and cat, and who had been receiving omalizumab from 
March 2007. Comparison of monitoring data collected from 
March 18 to April 16, 2005 (P judaica peak pollen season) with 
those from the same period in 2008 revealed a clear-cut decline 
in symptom scores: a constant score of 3 (maximum, 12) in 2005 
compared with absence of symptoms in 2008. Moreover, PEF 
values stabilized and increased, with a mean (SD) morning value 
of 437 (16) L/min in 2005 vs 498 (12) L/min in 2008, and mean 
evening values of 428 (6) L/min and 493 (6) L/min, in 2005 
and 2008, respectively. Both differences, which were analyzed 
using the t test for unpaired data, were statistically signifi cant 
(P<.0001). The concomitant pharmacological treatment (inhaled 
budesonide 1200 µg tid, nedocromil sodium 4 mg tid, formoterol 
12 µg bid, and montelukast 10 mg daily) remained unchanged 
over the 2 monitoring periods. 
Similar results were obtained in the other cases we 
analyzed. A 65-year-old housewife had a mean morning PEF of 
259 (9) L/min in 2005 compared with 308 (11) L/min in 2008 
(monitoring period, April 1-30; P<.0001). A 49-year-old male 
police offi cer had an average morning PEF of 536 (18) L/min 
in 2005 compared with 591 (15) L/min in 2008 (monitoring 
period, April 15-May 14; P<.0001).
Analysis of monitoring data for a 67-year-old housewife 
during December 13-January 11 in 2004/2005 and 2008/2009 
revealed a sharp reduction in PEF variability, from 26% 
to 8%, as assessed using the method of minimum morning 
prebronchodilator PEF over 1 week and expressed as a 
percentage of the recent best (Min%Max) [6].
We conclude that retrospective card-based monitoring 
of the symptom score and PEF followed by appropriate 
graphic rendering of the data collected is essential in the 
management of patients with poorly controlled severe asthma. 
This is particularly true when assessing the effi cacy of novel 
therapeutic agents such as omalizumab. The effects of this 
treatment in individual patients can be appraised using visual 
pattern recognition after generation of high-quality charts 
and quantitative determination of changes in PEF values and 
PEF variability.
